The dominant subset responsible for cross-presentation in peripheral tissues is the classical type 1 conventional dendritic cell, known as cDC1. In peripheral nonlymphoid sites such as skin, lung, and gut, this population is commonly identified by CD103 expression in mice and by CD141 also called BDCA3 in humans. These cells are specialized to capture exogenous antigens and load them onto MHC class I for CD8 T cell priming, a function essential for antiviral and antitumor immunity.
Identity and defining features
cDC1 express unique surface and functional markers including XCR1 and high levels of antigen-processing machinery that favor cross-presentation. Ralph M. Steinman Rockefeller University established the foundational concept that distinct dendritic cell subsets drive different T cell outcomes and laid the groundwork for recognizing specialized cross-presenting populations. Andreas Bachem German Cancer Research Center and colleagues further characterized human CD141 positive dendritic cells as efficient cross-presenters. These markers and functions are conserved across species but are not strictly identical between mice and humans, so translational interpretation requires care.
Mechanisms, causes, and consequences
Mechanistically, efficient cross-presentation by cDC1 depends on specialized antigen routing, controlled endosomal pH, and expression of proteins that limit premature antigen degradation. Kenneth L. Rock Dana-Farber Cancer Institute contributed key insights into antigen-processing pathways that enable exogenous antigens to access the MHC class I pathway. The developmental dependence of this subset on transcriptional programs has practical consequences: loss or deficiency of cDC1 impairs CD8 T cell responses and reduces tumor surveillance and antiviral immunity. Pierre Guermonprez Institut Pasteur described cellular pathways that support these activities.
Clinically and culturally, the prominence of cDC1 in peripheral tissues informs vaccine design and cancer immunotherapy strategies that aim to elicit cytotoxic T cell responses. Local environmental factors such as microbial exposure, tissue inflammation, and regional differences in healthcare access can influence cDC1 abundance and function, affecting vaccine efficacy across populations and territories. Environmentally, barriers like skin and mucosa shape how these cells sample antigens, linking territorial ecology to immune outcomes. Understanding and targeting cDC1 biology remains central to harnessing cross-presentation for protective and therapeutic immunity.